Olodaterol vs Umeclidinium/Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Beta-2 adrenergic receptor · full Chronic Obstructive Pulmonary Disease pipeline
Olodaterol
Marketed by Boehringer Ingelheim
NCT00782210 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled phase 3 trial in 624 patients with COPD comparing two doses of olodaterol (5 mcg and 10 mcg once daily) against placebo. Both pre-specified co-primary endpoints—FEV1 AUC 0-3h and trough FEV1 at 12 weeks—were met for both doses, with large, statistically significant differences versus placebo (p<0.0001 for all primary comparisons). The trial was adequately powered, used a regulator-accepted lung function endpoint for COPD, and the primary results were clearly positive.
Reported efficacy
Forced Expiratory Volume in One Second (FEV1) Area Under Curve 0-3 Hour (h) (AUC 0-3h) Response at Day 85 (12 Weeks) (1 hour (h) and 10 minutes (min) prior to dose on the first day of randomized treatment (baseline) to -10 min, 5 min, 15 min, 30 min, 1 h, 2 h, and 3 h relative to dose on Day 85); Trough FEV1 Response at Day 85 (12 Weeks) (1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and -1 h and - 10 mins prior to study drug at Day 85.): FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). (met)
Result source: NCT00782210
Umeclidinium/Vilanterol
Marketed by GlaxoSmithKline and partners
NCT01777334 · Phase 3 · completed
The trial randomly assigned 905 participants and used double blinding with tiotropium as an active comparator. Its primary endpoint was the clinical lung-function measure trough FEV1, and the primary comparison significantly favored umeclidinium/vilanterol.
Reported efficacy
Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) (met)
Result source: NCT01777334
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Olodaterol | Umeclidinium/Vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | 0.6 vs 0.7−0.1 vs placeboNCT007966533 other results
| —Trial running · NCT06474039 |
| Trough FEV1, change | 0.0 vs -0.1+0.1 vs placeboNCT00796653105 other results
| 0.2 vs 0.1vs TIONCT017773343 other results
|
| SGRQ total, change | 37.1 vs 42.0−4.9 vs placeboNCT0196435222 other results
| —Trial running · NCT06474039 |
| TDI focal score | 1.5 vs 1.1+0.4 vs placeboNCT0079665335 other results
| —Trial running · NCT06474039 |
Moderate or severe exacerbations, annualised rate
- Olodaterol
- 0.6 vs 0.7−0.1 vs placeboNCT00796653
3 other results
- 0.7 vs 0.6 NCT00793624
- 0.5 vs 0.7 NCT00796653
- 0.7 vs 0.6 NCT00793624
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
Trough FEV1, change
- Olodaterol
- 0.0 vs -0.1+0.1 vs placeboNCT00796653
105 other results
- 0.0 vs -0.1 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- -0.0 vs -0.1 NCT00796653
- 0.0 vs -0.1 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.2 vs 0.0 NCT01964352
- 0.2 vs -0.0 NCT02006732
- 0.2 vs 0.0 NCT01964352
- 0.2 vs -0.0 NCT02006732
- 0.2 vs 0.1 NCT01696058
- 0.2 vs 0.1 NCT01694771
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- -0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT01040689
- 0.1 vs 0.0 NCT01040728
- 0.0 vs -0.0 NCT00793624
- 0.1 vs 0.0 NCT00932646
- 0.1 vs -0.0 NCT00782210
- 0.1 vs 0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.0 vs -0.7 NCT00782210
- 0.0 vs -0.1 NCT00782509
- -0.0 vs -0.1 NCT00796653
- -0.0 vs -0.1 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.0 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.0 vs -0.1 NCT00782210
- 0.0 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.0 vs -0.0 NCT00793624
- 0.1 vs -0.0 NCT00782210
- 0.1 vs -0.0 NCT00782509
- 0.0 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT01040689
- 0.1 vs 0.0 NCT01040728
- 0.0 vs -0.0 NCT00793624
- 0.1 vs 0.0 NCT00932646
- 0.1 vs -0.0 NCT00782210
- 0.1 vs 0.0 NCT00782509
- 0.1 vs -0.0 NCT00796653
- 0.1 vs -0.0 NCT00793624
- 0.0 vs -0.7 NCT00782210
- 0.0 vs -0.1 NCT00782509
- -0.0 vs -0.1 NCT00796653
- 0.0 vs -0.1 NCT00793624
- 0.2 vs 0.1 NCT01969721
- 0.2 vs 0.1 NCT01969721
- 0.2 vs 0.1 NCT01536262
- 0.1 vs 0.1 NCT01536262
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00824382
- 0.0 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs 0.1 NCT00696020
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.1 NCT04223843
- 0.2 vs -0.1 NCT04223843
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT03673670
- 0.1 vs -0.0 NCT00824382
- 0.1 vs -0.0 NCT00452400
- 0.1 vs -0.0 NCT00452400
- 0.2 vs 0.1 NCT03673670
- 0.1 vs 0.1 NCT03240575
- Umeclidinium/Vilanterol
- 0.2 vs 0.1vs TIONCT01777334
3 other results
- 0.1 vs -0.0 NCT01899742
- 0.2 vs 0.2 NCT02487446
- 0.2 vs 0.2 NCT02487446
SGRQ total, change
- Olodaterol
- 37.1 vs 42.0−4.9 vs placeboNCT01964352
22 other results
- 38.0 vs 42.6 NCT02006732
- 37.6 vs 42.3 NCT02006732
- 37.9 vs 42.0 NCT01964352
- 38.9 vs 42.6 NCT02006732
- 38.4 vs 42.3 NCT02006732
- 41.2 vs 43.1 NCT01696058
- 38.8 vs 39.9 NCT00796653
- 36.9 vs 40.4 NCT00793624
- 38.6 vs 42.1 NCT00796653
- 38.2 vs 41.6 NCT00796653
- 37.7 vs 41.1 NCT00793624
- 38.2 vs 41.6 NCT00793624
- 40.2 vs 42.7 NCT00796653
- 37.0 vs 42.1 NCT00793624
- 39.6 vs 39.9 NCT00796653
- 38.5 vs 40.4 NCT00793624
- 39.0 vs 42.1 NCT00796653
- 38.8 vs 41.6 NCT00796653
- 38.6 vs 41.1 NCT00793624
- 38.8 vs 41.6 NCT00793624
- 40.1 vs 42.7 NCT00796653
- 39.3 vs 42.1 NCT00793624
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
TDI focal score
- Olodaterol
- 1.5 vs 1.1+0.4 vs placeboNCT00796653
35 other results
- 2.0 vs 1.5 NCT00796653
- 2.1 vs 2.0 NCT00793624
- 2.0 vs 1.5 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 2.0 vs 1.5 NCT00796653
- 2.2 vs 2.0 NCT00793624
- 2.0 vs 1.5 NCT00793624
- 1.8 vs 1.1 NCT00796653
- 2.3 vs 1.9 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 1.9 vs 2.0 NCT00793624
- 1.5 vs 1.2 NCT00796653
- 1.7 vs 1.7 NCT00793624
- 1.5 vs 1.0 NCT00796653
- 2.1 vs 1.7 NCT00793624
- 1.7 vs 1.1 NCT00796653
- 2.0 vs 1.4 NCT00793624
- 1.7 vs 1.0 NCT00796653
- 1.7 vs 1.0 NCT00793624
- 1.5 vs 1.1 NCT00796653
- 2.0 vs 1.9 NCT00793624
- 1.4 vs 1.1 NCT00796653
- 1.8 vs 2.0 NCT00793624
- 1.7 vs 1.2 NCT00796653
- 1.9 vs 1.7 NCT00793624
- 1.5 vs 1.0 NCT00796653
- 1.9 vs 1.7 NCT00793624
- 1.7 vs 1.1 NCT00796653
- 1.5 vs 0.3 NCT02006732
- 1.7 vs 0.1 NCT02006732
- 1.8 vs 1.4 NCT00793624
- 1.4 vs 1.0 NCT00796653
- 1.6 vs 1.0 NCT00793624
- 1.6 vs 0.3 NCT02006732
- 1.7 vs 0.1 NCT02006732
- Umeclidinium/Vilanterol
- —Trial running · NCT06474039
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Olodaterol: 7 of 7 rows · Umeclidinium/Vilanterol: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Olodaterol Rows use multiple source trials | Umeclidinium/Vilanterol Rows use multiple source trials |
|---|---|---|
| FEV1 AUC 12-24h absolute change · L | 0.16 vs 0.132 F+S 250/50 L @ 6wk2.5/5a,b,c,d NCT01969721 · Phase 3 · registry result, not featured evidence · combination show 1 more dose0.172 vs 0.132 F+S 250/50 L @ 6wk5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination | 0.2076 vs 0.2025 Umeclidinium/Vilanterol L @ 12wkb,c,d NCT02487446 · Phase 3 · registry result, not featured evidence |
| FEV1 AUC(0-24h absolute change · L | NA vs 0.122 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μga,e,b,c NCT03240575 · Phase 4 · registry result, not featured evidence · combination show 1 more dose0.174 vs 0.122 Fluticasone Propionate+Salmeterol L @ 12wk5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination | 0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wka,e,b,c NCT02487446 · Phase 3 · registry result, not featured evidence show 1 more dose0.2321 vs 0.2436 Umeclidinium/Vilanterol L @ 12wk NCT02487446 · Phase 3 · registry result, not featured evidence |
| FEV1 AUC0-12h absolute change · L | 0.139 vs -0.029 placebo L @ 12wk10 mcg qda,b,c NCT00782210 · Phase 3 show 1 more dose0.144 vs -0.029 placebo L @ 12wk5 mcg qd NCT00782210 · Phase 3 | 0.2543 vs 0.2848 Umeclidinium/Vilanterol L @ 12wkb,c NCT02487446 · Phase 3 · registry result, not featured evidence |
| Dropout rate | —10 mcgf NCT00782210 · Phase 3 show 77 more results16.9%10 mcg qd NCT00782210 · Phase 3 —5 mcg NCT00782210 · Phase 3 16.8%5 mcg qd NCT00782210 · Phase 3 —10 mcg NCT00782509 · Phase 3 16.6%10 mcg qd NCT00782509 · Phase 3 —5 mcg NCT00782509 · Phase 3 11.5%5 mcg qd NCT00782509 · Phase 3 15.4%10 mcg qd NCT00796653 · Phase 3 15.9%5 mcg qd NCT00796653 · Phase 3 —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 1.4%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 0%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence —5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 13.2%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 6.6%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination —2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination —5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 3.9%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 3%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 4.5%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 7.6%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination 5.3%2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 4.3%5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 5%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 4.9%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.1%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 17.3%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 15.9%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence —10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination — NCT02030535 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 5.8%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 3.8%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 2.4%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 4.5%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 8.8%5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 3.8%20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence | 11.7%62.5/25 µgg NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 6.9%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mcgf NCT00782210 · Phase 3 show 77 more results7.7%10 mcg qd NCT00782210 · Phase 3 —5 mcg NCT00782210 · Phase 3 8.2%5 mcg qd NCT00782210 · Phase 3 —10 mcg NCT00782509 · Phase 3 9.2%10 mcg qd NCT00782509 · Phase 3 —5 mcg NCT00782509 · Phase 3 4.8%5 mcg qd NCT00782509 · Phase 3 6.8%10 mcg qd NCT00796653 · Phase 3 6.9%5 mcg qd NCT00796653 · Phase 3 —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 0%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 0%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence —5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 6.6%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 5.3%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination —2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination —5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 1.5%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 1%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 3.7%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination 5.3%2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 3.6%5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.5%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 4.9%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 3.2%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence —10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence —5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 6.7%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 7%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence —10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence —6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination —1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination — NCT02030535 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence —tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination —tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.7%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.3%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.2%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence —2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 1.1%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.2%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination —10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 0%10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 6.3%5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence 1.2%2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence | 4%62.5/25 µgg NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results—62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 — NCT02487446 · Phase 3 · registry result, not featured evidence —27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence —62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Serious AEs | 20.8%10 mcgf NCT00782210 · Phase 3 show 77 more results—10 mcg qd NCT00782210 · Phase 3 18.8%5 mcg NCT00782210 · Phase 3 —5 mcg qd NCT00782210 · Phase 3 17.1%10 mcg NCT00782509 · Phase 3 —10 mcg qd NCT00782509 · Phase 3 15.3%5 mcg NCT00782509 · Phase 3 —5 mcg qd NCT00782509 · Phase 3 17.5%10 mcg qd NCT00796653 · Phase 3 14.7%5 mcg qd NCT00796653 · Phase 3 1.9%5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT04223843 · Phase 4 · registry result, not featured evidence · combination 3.9%5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination —5μg/5μg NCT03240575 · Phase 4 · registry result, not featured evidence · combination 4.8%5/5 μg NCT02853123 · Phase 4 · registry result, not featured evidence · combination 1.8%5/5 mcg NCT02683109 · Phase 4 · registry result, not featured evidence 3.9%5/5 NCT02629965 · Phase 3 · registry result, not featured evidence · combination 10.5%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 3.9%5/5 μg NCT02085161 · Phase 3 · registry result, not featured evidence · combination 2.8%2.5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 3.2%5/5 NCT01969721 · Phase 3 · registry result, not featured evidence · combination 4.9%5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT01964352 · Phase 3 · registry result, not featured evidence · combination —5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 3%5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2%2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination —2.5 μg + 5 μg NCT02006732 · Phase 3 · registry result, not featured evidence · combination 4.2%5 μg and 18 μg NCT01696058 · Phase 3 · registry result, not featured evidence · combination —2.5 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 6.8%2.5 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination —5.0 / 5.0 µg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.9%5.0 / 5.0 μg NCT01525615 · Phase 3 · registry result, not featured evidence · combination 15%2.5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.3%5 / 5 μg NCT01536262 · Phase 3 · registry result, not featured evidence · combination 7.1%5µg olodaterol + 18µg tiotropium NCT01694771 · Phase 3 · registry result, not featured evidence 2.1%10 mcg NCT01040130 · Phase 3 · registry result, not featured evidence 2%5 mcg NCT01040130 · Phase 3 · registry result, not featured evidence 2%10 mcg NCT01040793 · Phase 3 · registry result, not featured evidence 5.3%5 mcg NCT01040793 · Phase 3 · registry result, not featured evidence 0%10 mcg NCT01040689 · Phase 3 · registry result, not featured evidence 1%5 mcg NCT01040689 · Phase 3 · registry result, not featured evidence 7.1%10 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 2.6%5 mcg NCT01040728 · Phase 3 · registry result, not featured evidence 11.6%10 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 14.5%5 mcg qd NCT00793624 · Phase 3 · registry result, not featured evidence 3.2%10 mcg NCT00932646 · Phase 3 · registry result, not featured evidence 4.3%5 mcg NCT00932646 · Phase 3 · registry result, not featured evidence 1.4%6 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 0%1.5 mg NCT03673670 · Phase 2 · registry result, not featured evidence · combination 0% NCT02030535 · Phase 2 · registry result, not featured evidence · combination 1.8%10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 3.7%5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence 0%tiotropium 5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 4.5%tiotropium 2.5 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 2.7%tiotropium 2.5 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 10 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 0.9%tiotropium 1.25 mcg + olodaterol 5 mcg NCT01040403 · Phase 2 · registry result, not featured evidence · combination 3.5%10mcg NCT00824382 · Phase 2 · registry result, not featured evidence 1.3%5mcg NCT00824382 · Phase 2 · registry result, not featured evidence 3.6%2mcg NCT00824382 · Phase 2 · registry result, not featured evidence 0%10 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence 0%5 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 0%5 mcg qd NCT00846768 · Phase 2 · registry result, not featured evidence 2.1%2 mcg Bid NCT00846768 · Phase 2 · registry result, not featured evidence 0%5/10 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 3.4%5/2 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 1.1%5/5 μg NCT00696020 · Phase 2 · registry result, not featured evidence · combination 2.3%10 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —10 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%5 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —5 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%20 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —20 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence 2.5%2 mcg NCT00452400 · Phase 2 · registry result, not featured evidence —2 mcg qd NCT00452400 · Phase 2 · registry result, not featured evidence | 3.5%62.5/25 µgg NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results1.7%62.5/25 µg once daily NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 3.8% NCT02487446 · Phase 3 · registry result, not featured evidence 5%27.5/12.5 Bid NCT02487498 · Phase 3 · registry result, not featured evidence 2.8%62.5/25 µg NCT01899742 · Phase 3 · registry result, not featured evidence 0.5%62.5/25 µg NCT02014480 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mcgf chronic obstructive pulmonary disease 23.7% (placebo 27.3%) nasopharyngitis 6.3% (placebo 6.2%) upper respiratory tract infection 6.3% (placebo 7.2%) NCT00782210 · Phase 3 show 57 more results5 mcg chronic obstructive pulmonary disease 19.2% (placebo 27.3%) nasopharyngitis 10.1% (placebo 6.2%) upper respiratory tract infection 10.1% (placebo 7.2%) NCT00782210 · Phase 3 10 mcg chronic obstructive pulmonary disease 21.7% (placebo 19.9%) nasopharyngitis 11.5% (placebo 8.3%) upper respiratory tract infection 10.1% (placebo 7.9%) NCT00782509 · Phase 3 5 mcg chronic obstructive pulmonary disease 18.7% (placebo 19.9%) upper respiratory tract infection 9.6% (placebo 7.9%) nasopharyngitis 9.1% (placebo 8.3%) NCT00782509 · Phase 3 10 mcg qd chronic obstructive pulmonary disease 20.5% (placebo 21.7%) nasopharyngitis 12% (placebo 9.4%) upper respiratory tract infection 6.4% (placebo 7.7%) NCT00796653 · Phase 3 5 mcg qd chronic obstructive pulmonary disease 17.2% (placebo 21.7%) nasopharyngitis 15.5% (placebo 9.4%) upper respiratory tract infection 6% (placebo 7.7%) NCT00796653 · Phase 3 5μg/5μg chronic obstructive pulmonary disease 5.3% NCT03240575 · Phase 4 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 13.3% viral upper respiratory tract infection 13.3% cough 4.8% NCT02853123 · Phase 4 · registry result, not featured evidence · combination 5/5 mcg chronic obstructive pulmonary disease 8.1% NCT02683109 · Phase 4 · registry result, not featured evidence 5/5 viral upper respiratory tract infection 10% NCT02629965 · Phase 3 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 17.1% (placebo 21.3%) nasopharyngitis 13.2% (placebo 10.7%) dyspnoea 2.6% (placebo 2.7%) NCT02085161 · Phase 3 · registry result, not featured evidence · combination 5/5 μg chronic obstructive pulmonary disease 15.8% (placebo 21.3%) nasopharyngitis 5.3% (placebo 10.7%) back pain 2.6% (placebo 5.3%) NCT02085161 · Phase 3 · registry result, not featured evidence · combination 2.5/5 nasopharyngitis 5.6% chronic obstructive pulmonary disease 4.7% NCT01969721 · Phase 3 · registry result, not featured evidence · combination 5/5 chronic obstructive pulmonary disease 8.1% nasopharyngitis 5.4% NCT01969721 · Phase 3 · registry result, not featured evidence · combination 5 μg + 5 μg chronic obstructive pulmonary disease 4.4% (placebo 9.8%) nasopharyngitis 3.4% (placebo 5.9%) NCT01964352 · Phase 3 · registry result, not featured evidence · combination 2.5 μg + 5 μg chronic obstructive pulmonary disease 7.9% (placebo 9.8%) nasopharyngitis 4.5% (placebo 5.9%) NCT01964352 · Phase 3 · registry result, not featured evidence · combination 5 μg + 5 μg chronic obstructive pulmonary disease 4.5% (placebo 6.9%) cough 1.5% (placebo 5.9%) dyspnoea 1% (placebo 6.9%) NCT02006732 · Phase 3 · registry result, not featured evidence · combination 2.5 μg + 5 μg chronic obstructive pulmonary disease 8.4% (placebo 6.9%) cough 2.5% (placebo 5.9%) dyspnoea 2% (placebo 6.9%) NCT02006732 · Phase 3 · registry result, not featured evidence · combination 5 μg and 18 μg chronic obstructive pulmonary disease 8.5% (placebo 7.7%) NCT01696058 · Phase 3 · registry result, not featured evidence · combination 2.5 / 5.0 μg chronic obstructive pulmonary disease 7.5% (placebo 11.4%) cough 6.8% (placebo 6.1%) nasopharyngitis 6.8% (placebo 4.5%) NCT01525615 · Phase 3 · registry result, not featured evidence · combination 5.0 / 5.0 μg chronic obstructive pulmonary disease 7.2% (placebo 11.4%) nasopharyngitis 2.9% (placebo 4.5%) cough 1.4% (placebo 6.1%) NCT01525615 · Phase 3 · registry result, not featured evidence · combination 2.5 / 5 μg nasopharyngitis 27.5% bronchitis 12.5% chronic obstructive pulmonary disease 10% NCT01536262 · Phase 3 · registry result, not featured evidence · combination 5 / 5 μg nasopharyngitis 26.8% chronic obstructive pulmonary disease 17.1% bronchitis 14.6% NCT01536262 · Phase 3 · registry result, not featured evidence · combination 5µg olodaterol + 18µg tiotropium chronic obstructive pulmonary disease 10.6% NCT01694771 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 3.5% (placebo 5.6%) NCT01040130 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 6.8% (placebo 5.6%) NCT01040130 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 2.7% (placebo 6%) NCT01040793 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 5.3% (placebo 6%) NCT01040793 · Phase 3 · registry result, not featured evidence 10 mcg nasopharyngitis 4% (placebo 7.8%) chronic obstructive pulmonary disease 2% (placebo 3.9%) NCT01040689 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 7.9% (placebo 3.9%) nasopharyngitis 5.9% (placebo 7.8%) NCT01040689 · Phase 3 · registry result, not featured evidence 10 mcg nasopharyngitis 3.5% (placebo 3.7%) chronic obstructive pulmonary disease 2.7% (placebo 3.7%) NCT01040728 · Phase 3 · registry result, not featured evidence 5 mcg nasopharyngitis 7% (placebo 3.7%) chronic obstructive pulmonary disease 5.2% (placebo 3.7%) NCT01040728 · Phase 3 · registry result, not featured evidence 10 mcg qd chronic obstructive pulmonary disease 27.6% (placebo 22.7%) nasopharyngitis 11.1% (placebo 6.7%) cough 5.8% (placebo 3.1%) NCT00793624 · Phase 3 · registry result, not featured evidence 5 mcg qd chronic obstructive pulmonary disease 29.5% (placebo 22.7%) nasopharyngitis 9.7% (placebo 6.7%) upper respiratory tract infection 7.5% (placebo 6.7%) NCT00793624 · Phase 3 · registry result, not featured evidence 10 mcg chronic obstructive pulmonary disease 7.4% (placebo 5.3%) upper respiratory tract infection 5.3% (placebo 4.3%) NCT00932646 · Phase 3 · registry result, not featured evidence 5 mcg chronic obstructive pulmonary disease 5.4% (placebo 5.3%) upper respiratory tract infection 4.3% (placebo 4.3%) NCT00932646 · Phase 3 · registry result, not featured evidence 6 mg headache 6.8% (placebo 1.3%) ventricular extrasystoles 4.1% (placebo 0%) chronic obstructive pulmonary disease 2.7% (placebo 1.3%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination 1.5 mg headache 6.7% (placebo 1.3%) ventricular extrasystoles 2.7% (placebo 0%) accelerated idioventricular rhythm 1.3% (placebo 0%) NCT03673670 · Phase 2 · registry result, not featured evidence · combination nasopharyngitis 1.9% (placebo 5.7%) NCT02030535 · Phase 2 · registry result, not featured evidence · combination 10 mcg nasopharyngitis 6.4% chronic obstructive pulmonary disease 5.5% NCT01040403 · Phase 2 · registry result, not featured evidence 5 mcg nasopharyngitis 10.2% chronic obstructive pulmonary disease 5.6% NCT01040403 · Phase 2 · registry result, not featured evidence tiotropium 5 mcg + olodaterol 10 mcg chronic obstructive pulmonary disease 3.6% nasopharyngitis 1.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 5 mcg + olodaterol 5 mcg chronic obstructive pulmonary disease 7.3% nasopharyngitis 2.8% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 10 mcg nasopharyngitis 3.6% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 2.5 mcg + olodaterol 5 mcg nasopharyngitis 7.1% chronic obstructive pulmonary disease 2.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 10 mcg nasopharyngitis 7.3% chronic obstructive pulmonary disease 6.4% NCT01040403 · Phase 2 · registry result, not featured evidence · combination tiotropium 1.25 mcg + olodaterol 5 mcg nasopharyngitis 11% chronic obstructive pulmonary disease 3.7% NCT01040403 · Phase 2 · registry result, not featured evidence · combination 10mcg nasopharyngitis 5.8% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 5mcg nasopharyngitis 3.8% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 2mcg nasopharyngitis 10.7% (placebo 3.8%) myalgia 0% (placebo 5.1%) NCT00824382 · Phase 2 · registry result, not featured evidence 10 mcg qd nasopharyngitis 6.5% dyspnoea 0% NCT00846768 · Phase 2 · registry result, not featured evidence 5 mcg Bid nasopharyngitis 6.5% dyspnoea 2.2% NCT00846768 · Phase 2 · registry result, not featured evidence 5 mcg qd dyspnoea 6.4% nasopharyngitis 2.1% NCT00846768 · Phase 2 · registry result, not featured evidence 2 mcg Bid nasopharyngitis 2.1% dyspnoea 0% NCT00846768 · Phase 2 · registry result, not featured evidence 10 mcg nasopharyngitis 4.7% (placebo 1.3%) headache 3.5% (placebo 5.1%) cough 2.3% (placebo 2.5%) NCT00452400 · Phase 2 · registry result, not featured evidence 5 mcg cough 7.5% (placebo 2.5%) nasopharyngitis 7.5% (placebo 1.3%) dyspnoea 2.5% (placebo 7.6%) NCT00452400 · Phase 2 · registry result, not featured evidence 20 mcg dyspnoea 3.8% (placebo 7.6%) cough 2.5% (placebo 2.5%) nasopharyngitis 2.5% (placebo 1.3%) NCT00452400 · Phase 2 · registry result, not featured evidence 2 mcg cough 4.9% (placebo 2.5%) dyspnoea 3.7% (placebo 7.6%) headache 3.7% (placebo 5.1%) NCT00452400 · Phase 2 · registry result, not featured evidence | 62.5/25 µgg headache 8.8% nasopharyngitis 6.2% cough 2.9% NCT01777334 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 show 5 more results62.5/25 µg once daily nasopharyngitis 4% headache 3.5% NCT01716520 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3 chronic obstructive pulmonary disease 10.6% nasopharyngitis 5.6% oropharyngeal pain 2.9% NCT02487446 · Phase 3 · registry result, not featured evidence 27.5/12.5 Bid chronic obstructive pulmonary disease 14.8% bronchitis 3.3% sinusitis 1.8% NCT02487498 · Phase 3 · registry result, not featured evidence 62.5/25 µg nasopharyngitis 7.3% headache 6.5% NCT01899742 · Phase 3 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 6 weeks versus 12 weeks.
- eTrial phases differ: Phase 4 versus Phase 3.
- fPopulation comparability has not been reviewed for these studies.
- gPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olodaterol
show 68 more results
show 84 more results
show 59 more results
show 90 more results
show 58 more results
show 9 more results
show 15 more results
show 15 more results
show 15 more results
show 15 more results
show 31 more results
show 11 more results
+ 93 further endpoints in the CSV export.
Umeclidinium/Vilanterol
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Olodaterol's landscape · Umeclidinium/Vilanterol's landscape